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The unequivocal success of antiretroviral therapy 
(ART) in controlling HIV replication and restoring 
immunity has been tempered by the recognition that 
metabolic diseases, such as diabetes mellitus (DM), 
are increasing in incidence among people living 
with HIV. Studies from high-income countries have reported that 
the incidence of diabetes in HIV-infected adults on ART is between 
1% and 10%.[1] Conventional risk factors, such as obesity, ageing 
and male sex, are important determinants of diabetes.[2,3] However, 
specific antiretrovirals (ARVs)[3] and ARV-related weight gain and 
lipodystrophy[4,5] are recognised risk factors. High pre-ART viral 
loads and low baseline CD4+ counts may also increase the risk of 
insulin resistance and accelerate the pathogenesis of diabetes.[5] 
The association between HIV infection and DM in sub-Saharan 
Africa (SSA) has not been well documented.[6,7] While diabetes 
incidence is increasing in the general population in southern Africa,[8,9] 
there is very little describing the incidence and determinants of 
diabetes among HIV-infected adults in this region. 
Objective
To assess the characteristics associated with HIV and DM at the time 
of ART initiation in patients in Botswana. 
Methods
A retrospective case-control study was conducted at 4 sites between 
February 2011 and November 2012. DM was defined according to 
the World Health Organization criteria.[10] Cases were identified by 
searching the medical records of patients who had accessed care 
at diabetes clinics at 2 semi-urban facilities (in Orapa and Kanye) 
and 2 urban facilities (in Gaborone and Francistown). Patients who 
developed diabetes on ART or who had pre-existing DM before 
initiating ART were included if they had either 5 consecutive CD4+ 
count measurements post-ART initiation or had been taking ART 
for at least 2 years. Those with confirmed insulin-dependent type 1 
diabetes were excluded. At each site, controls were selected by a 
systematic process – every 20th file in the adult HIV clinic registry 
was retrieved.
Two controls per case were matched preferentially for age 
(±2 years) and sex. The medical records of all cases and controls were 
reviewed to extract demographic and clinical data including weight, 
ART regimen, ART adherence, co-morbid disease and baseline pre-
ART CD4+ counts and viral loads. 
Primary analysis using conditional logistic regression was employed 
to estimate univariate odds ratios (ORs) for each characteristic. 
Conditioning was based on 6 age-sex categories (gender within 3 age 
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Background. There is little in the literature on HIV and diabetes mellitus (DM) in sub-Saharan Africa.
Objective. To assess the characteristics of HIV and DM in patients on antiretroviral therapy (ART) in Botswana.
Methods. A retrospective case-control study was conducted at 4 sites. Each HIV-infected patient with DM (n=48) was matched with 2 HIV-
infected controls (n=108) by age (±2 years) and sex. Primary analysis was conditional logistic regression to estimate univariate odds and 
95% confidence intervals (CIs) for each characteristic.
Results. There was no significant association between co-morbid diseases, tuberculosis, hypertension or cancer and risk of diabetes. DM 
patients were more likely to have higher pre-ART weight (odds ratio (OR) 1.09; 95% CI 1.04 - 1.14). HIV-infected adults >70 kg were 
significantly more likely to have DM (OR 12.30; 95% CI 1.40 - 107.98). Participants on efavirenz (OR 4.58; 95% CI 1.44 - 14.57) or protease 
inhibitor therapy (OR 20.7; 95% CI 1.79 - 240.02) were more likely to have DM. Neither mean pre-ART CD4 cell count (OR 1.0; 95% CI 
0.99 - 1.01) nor pre-ART viral load >100 000 copies/ml (OR 0.71; 95% CI 0.21 - 2.43) were associated with a significant risk of diabetes. 
Conclusions. These findings suggest a complex interrelation among traditional host factors and treatment-related metabolic changes in the 
pathogenesis of DM inpatients receiving ART. Notably, pre-ART weight, particularly if >70 kg, is associated with the diagnosis of diabetes 
in HIV-infected patients in Botswana. 
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groups: <40, 40 - 49, and ≥50 years). Statistical 
analyses were performed using STATA 
software version 12. All tests of significance 
were 2-sided with p≤0.05 designated as 
statistically significant.
This study was approved by the 
Institutional Review Boards of Princess 
Marina and Nyangabgwe Referral Hospitals 
and the Botswana Ministry of Health. 
Results
In total, there were 48 cases (28 females, 
20 males, age mean 46.4  years ± standard 
deviation (SD) 9.9) and 108 controls 
(57  females, 51 males, age mean ±SD 
43.6±8 years) who had initiated ART between 
January 2001 and February 2011. Data 
were available on prescribed anti-diabetic 
medications in the majority of cases (n=28): 
21% (n=6) were on metformin, 60% (n=17) 
on metformin and glibenclamide and 18% 
(n=5) on an insulin-based regimen. Cases 
were matched with 108 HIV-infected control 
patients without DM. Table 1 summarises the 
baseline characteristics of both cohorts. 
There was no significant association 
between the risk of having DM and either 
hypertension, active tuberculosis, cancer 
or reported adherence of <95%. However, 
undocumented adherence to ART was 
associated with an increased diabetes risk.
Weight at initiation of ART was 
significantly associated with increased risk of 
diabetes. Furthermore, the odds of DM with 
a pre-ART body weight of >70 kg was over 
12 times that for a body weight of <50  kg. 
Univariate analysis demonstrated that both 
efavirenz (EFV) and protease inhibitor (PI) 
therapies were associated with increased 
odds of diabetes. While multivariate analysis 
suggested that weight was confounding the 
effect of the drug regimen, the sample size 
was too small to draw firm conclusions. 
Mean CD4+ count at the time of ART 
initiation was not significantly higher in 
individuals with DM than controls. However, 
there was a non-significant trend towards 
increased risk of diabetes at a higher CD4+ 
count – patients with pre-ART CD4+ counts 
of >180 cells/μl were twice as likely to have 
DM compared with those with pre-ART 
CD4+ counts of <60  cells/μl. Baseline viral 
load >100 000 copies/ml was not associated 
with an increased risk of diabetes. 
Discussion
In this case-control study, there were several 
notable findings. Firstly, diabetic patients 
with HIV had higher baseline weight 
compared with non-diabetics. Individuals 
with pre-ART weights of >70 kg had 
significantly higher risk of having diabetes, 
compared with those with baseline weights 
of <50 kg. This finding is consistent with 
established data that insulin resistance 
correlates with increased weight gain and 
obesity.[5] However, it is an important finding 
in this population since initiation of ART 
is itself associated with rapid weight gain.
[2] Furthermore, the importance of targeted 
Table 1. Characteristics of subjects prior to initiation of ART
Characteristic
Diabetes cases* 
(N=48)
Non-diabetes 
controls (N=108) OR (95% CI)†
ART,‡ n (%)
1st NVP 4 (8.3) 34 (31.5) 1
1st EFV 41 (85.4) 73 (67.6) 4.58 (1.44 - 14.57)
2nd PI 3 (6.2) 1 (0.9) 20.7 (1.79 - 240.02)
Adherence, n (%)
>95% (excellent) 26 (54.2) 75 (69.4) 1
<95% 2 (4.2) 11 (10.2) 0.45 (0.09 - 2.21)
Unknown 20 (41.7) 22 (20.4) 2.28 (1.07 - 4.85)
Body weight (kg), n (%)
Total, mean±SD (n) 70.6±13.3 (28) 59.4±10.5 (69) 1.09 (1.04 - 1.14)
<50 1 (2.1) 13 (12) 1
50 - 59.9 4 (8.3) 22 (20.4) 2.23 (0.22 - 22.44)
60 - 69.9 9 (18.8) 20 (18.5) 5.18 (0.58 - 46.05)
>70 14 (29.2) 14 (13) 12.30 (1.4 - 107.98)
Undetermined 20 (41.7) 39 (36.1) 5.89 (0.71 - 48.68)
CD4+ count (cells/μl), n (%)
Total, mean±SD 148.3±128.3 120.6±72.8 1.003 (0.99 - 1.01)
<60 8 (16.7) 28 (25.9) 1
60 - 119 11 (22.9) 27 (25.0) 1.45 (0.48 - 4.36)
120 - 179 16 (33.3) 32 (29.6) 1.53 (0.56 - 4.12)
>180 13 (27.1) 21 (19.4) 2 (0.68 - 5.91)
Viral load (copies/ml), n (%)
Median 74 750 (18) 108 122 (24)
IQR 11 800 - 43 700 14 000 - 500 000
<100 000 10 (20.8) 12 (11.1) 1
>100 000 8 (16.7) 12 (11.1) 0.71 (0.21 - 2.43)
Unknown 30 (62.5) 84 (77.8) 0.39 (0.15 - 1)
Log viral load, mean±SD (n) 10.9±2.4 (18) 11±2.6 (24) 0.96 (0.75 - 1.22)
Tuberculosis, n (%)
No 46 (95.8) 99 (91.7) 1
Yes 2 (4.2) 9 (8.3) 0.54 (0.11 - 2.64)
Cancer, n (%)
No 44 (91.7) 102 (94.4) 1
Yes 4 (8.3) 6 (5.6) 1.45 (0.38 - 5.49)
Hypertension, n (%)
No 39 (81.3) 91 (84.3) 1
Yes 9 (18.8) 17 (15.7) 1.22 (0.50 - 2.98)
ART = antiretroviral therapy; OR = odds ratio; CI = confidence intervals;ARV = antiretroviral; NVP = nevirapine;  
EFV = efavirenz; PI = protease inhibitor; SD = standard deviation; IQR = interquartile range.
*Type 2 or unspecified diabetes.
†Conditional logistic regression.
‡ Refers to first-line regimen in Botswana – either non-nucleoside reverse transcriptase inhibitor-based regimen (NVP or 
EFV) or second-line PI-based regimen (lopinavir/ritonavir).
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risk reduction strategies for overweight and obese individuals starting 
ART is highlighted. 
Secondly, there were associations between both EFV and PI 
exposures and DM. While there is substantial literature indicating 
that ART plays a causative or permissive role in the pathogenesis 
of DM in HIV-infected patients, most research has demonstrated a 
link between DM and thymidine analogues[3] and PI therapy.[3,11] Our 
finding that EFV was associated with diabetes is especially notable 
given that EFV is part of first-line ART regimens across SSA because 
of its perceived lower toxicity compared with nevirapine. Researchers 
in Cape Town, South Africa found that EFV was significantly 
associated with impaired glucose tolerance even after controlling 
for body mass index and waist circumference.[7] Participants in 
that study had all been on EFV for at least 6 months at the time of 
enrolment, suggesting that EFV may accelerate insulin resistance. 
We speculate that the effect of EFV in our analysis was mediated by 
weight – those with a priori obesity on EFV were more likely to have 
DM. Unfortunately, our sample size was not large enough to prove 
conclusively that this was the case. More prospective research is 
warranted to elucidate how EFV influences diabetogenesis, especially 
in individuals with pre-ART weights >70 kg.
Thirdly, our analysis failed to demonstrate an association between 
HIV-specific factors and DM. Neither baseline CD4+ count, nor pre-
ART viral load was associated with risk of diabetes. These findings 
are consistent with data from prospective analyses that have failed to 
demonstrate associations between CD4+ nadir or baseline viraemia 
and diabetes.[2,3] Nevertheless, more research is required to explore the 
relationship between immune reconstitution and insulin resistance. 
Our analysis did not demonstrate any association between specific 
co-morbidities, tuberculosis, hypertension and malignancy, and 
diabetes. Data concerning co-morbidities such as dyslipidaemia, 
cardiovascular disease or hepatitis C co-infection that may have 
provided insights into the pathogenesis of DM in our setting were 
not collected. 
No relationship between diabetes and ART adherence emerged. 
While there is clear evidence that psychosocial factors are important 
in the pathogenesis of DM in HIV-uninfected adults in southern 
Africa,[9] more rigorous investigation is necessary to determine 
the role of psychosocial determinants in both ART adherence and 
diabetogenesis in HIV-infected adults. 
The study has several limitations. Because of the cross-sectional 
study design we were able only to evaluate associations between 
the examined variables and diabetes. Given the retrospective 
nature of this study, we were also unable to determine whether 
patients had developed diabetes before or after the initiation of ART. 
Consequently, we could not assess whether HIV infection or ARV 
drug exposure played a causal role in the pathogenesis. Furthermore, 
despite excluding all confirmed type 1 diabetics, we could not exclude 
those in whom diabetes may have developed secondary to the use of 
drugs such as pentamidine or corticosteroids. 
There were several traditional risk factors for the development of 
DM, such as family history, waist circumference, ethnicity, sedentary 
lifestyle, which were not included in our analysis. It would be valuable to 
assess the impact of these determinants in our setting, particularly given 
the increasing number of older, overweight persons living with HIV in 
southern Africa.[6] We were also unable to assess the potential impact 
of nucleoside reverse transcriptase inhibitors such as zidovudine and 
stavudine, both of which have been associated with an increased risk of 
diabetes.[2,11] Increased visceral fat and lipodystrophy, caused indirectly 
and directly by ARVs, may also contribute to disordered glucose 
homeostasis. The impact of lipodystrophy on the development of DM 
was not evaluated, given the retrospective nature of the study.
Conclusions
This case-control study suggests a complex interrelation among 
traditional host factors and treatment-related metabolic changes in 
the pathogenesis of DM. Patients with higher pre-ART weight and 
those exposed to EFV or a PI were more likely to have DM. Larger 
prospective studies are needed to delineate the relative contribution 
of other factors among people living with diabetes in southern Africa. 
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